神經(jīng)鈣黏蛋白(NCAD)多克隆抗體
Polyclonal Antibody to N-cadherin (NCAD)
CDw325; CD325; CDHN; CDH2; Cadherin 2 Type 1; N-Cadherin
- 編號PAB481Ra01
- 物種Rattus norvegicus (Rat,大鼠) 相同的名稱,不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 免疫原 RPB481Ra01-神經(jīng)鈣黏蛋白(NCAD)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液(pH7.4,containing 0.05% Proclin-300,50% glycerol)
- 性狀液體
- 濃度500μg/mL
- 且適物種Homo sapiens (Human,人), Mus musculus (Mouse,小鼠)
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細胞術(shù),請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 652 ¥ 1520 ¥ 2172 ¥ 5430 ¥ 21720
- 欲了解實際交易價格和更多情況,請與當?shù)亟?jīng)銷商聯(lián)系!
特異性
該抗體是針對NCAD的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實驗中能識別NCAD。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當?shù)臈l件下存儲,損失率低于5%。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Rattus norvegicus (Rat,大鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPB481Ra02 | 神經(jīng)鈣黏蛋白(NCAD)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB481Ra03 | 神經(jīng)鈣黏蛋白(NCAD)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB481Ra01 | 神經(jīng)鈣黏蛋白(NCAD)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB481Ra02 | 神經(jīng)鈣黏蛋白(NCAD)多克隆抗體 | WB; IHC; ICC; IP. |
PAB481Ra03 | 神經(jīng)鈣黏蛋白(NCAD)多克隆抗體 | WB; IHC; ICC; IP. |
PAB481Ra01 | 神經(jīng)鈣黏蛋白(NCAD)多克隆抗體 | WB; IHC; ICC; IP. |
LAB481Ra71 | 神經(jīng)鈣黏蛋白(NCAD)多克隆抗體(生物素標記) | WB; IHC; ICC. |
參考文獻
雜志 | 參考文獻 |
Toxicology Letters | Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients. [Pubmed: 23830989] |
British journal of haematology | Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. [Pubmed: 23438504] |
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY | Elevated Cerebrospinal Fluid and Plasma N-Cadherin in Alzheimer Disease [Pubmed: 32296844] |
Cell Biol Toxicol | ZNF471 modulates EMT and functions as methylation regulated tumor suppressor with diagnostic and prognostic significance in cervical cancer [33566221] |
CELL BIOLOGY AND TOXICOLOGY | Metastatic suppression by DOC2B is mediated by inhibition of epithelial-mesenchymal transition and induction of senescence [33758996] |
Pharmacol Res | DOC2B is a Negative Regulator of Wnt/β-catenin Signaling Pathway in Cervical Cancer [Pubmed:35500882] |
留言咨詢